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Estimating the burden of rheumatoid arthritis 
in Africa: A systematic analysis
Background Rheumatoid arthritis (RA) has an estimated worldwide 
prevalence of 1%. It is one of the leading causes of chronic morbid-
ity in the developed world, but little is known about the disease bur-
den in Africa. RA is often seen as a minor health problem and has 
been neglected in research and resource allocation throughout Af-
rica despite potentially fatal systemic manifestations. This review 
aims to identify all relevant epidemiological literature pertaining to 
the occurrence of RA in Africa and calculate the prevalence and bur-
den of disease.
Methods A systematic literature review of Medline, Embase and 
Global Health Library retrieved a total of 335 publications, of which 
10 population studies and 11 hospital studies met pre–defined min-
imum criteria for relevance and quality. Data on prevalence was ex-
tracted, analysed and compared between population and hospital 
studies. Differences between genders were also analysed.
Results The estimated crude prevalence of RA in Africa based on 
the available studies was 0.36% in 1990, which translates to a bur-
den of 2.3 million affected individuals in 1990. Projections for the 
African population in 2010 based on the same prevalence rates 
would suggest a crude prevalence of 0.42% and the burden in-
creased to 4.3 million. Only 2 population studies have been con-
ducted after 1990, so projections for 2010 are uncertain. Hospital–
based studies under–report the prevalence by about 6 times in 
comparison to population–based studies.
Conclusion The availability of epidemiological information on RA 
in Africa is very limited. More studies need to be conducted to esti-
mate the true burden and patterns of RA before appropriate health 
policies can be developed.
Rheumatoid arthritis (RA) is one of the most common chronic diseases, 
with an estimated global prevalence of 1% [1], and is one of the leading 
causes of chronic morbidity in industrialised nations [2]. RA is an auto-
immune disease that primarily affects the small joints of the hand, wrist, 
and feet. If left untreated, it can lead to extensive erosion of the cartilage, 
causing deformity and disability [3]. Common symptoms include pain 
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and stiffness, but prolonged disease is also associated with 
psychological problems such as depression [3]. The cause 
of onset is currently unknown, but a genetic susceptibility 
to an environmental trigger seems the most plausible [4]. 
Various bacteria and viruses have been suggested as the ini-
tial trigger; with a form of molecular mimicry imitating hu-
man antigens activating an immune response against the 
host's own cells [3]. The disabilities caused by RA can have 
extensive impacts on quality of life, with loss of productiv-
ity due to damaged and deformed joints inhibiting fine 
movements of the hand [5]. This disability can lead to a 
loss of career and sources of income, which is a particular 
problem in low income settings. For a certain subset of the 
population, jobs in Africa involve a level of manual labour 
and the resource–starved African states can afford only lim-
ited or no welfare support for disabled individuals [2]. 
Along with the increase in non–communicable diseases 
(NCD) in developing countries, an increase in RA occur-
rence could stress medical services that are already strug-
gling with a high burden of acute infectious illness to an 
extent that they may be unable to cope with the fast chang-
ing patterns of disease distribution seen in Africa today [6].
RA is not just a debilitating disease of small joints. It is also 
associated with significant extra–articular manifestations 
and mortality, with an average decreased life expectancy of 
3–7 years in America [3]. Complications of RA can have 
extremely serious consequences, most commonly involv-
ing the respiratory, cardiac and visual systems [7]. The dis-
ease has been shown to increase the risk of stroke by up to 
65% and through the development of rheumatic nodules 
the risk of myocardial infarctions, pleural effusions and 
lung infections is increased [7,8]. Since RA is an autoim-
mune disease, it can affect any part of the body, especially 
those that relay on small vessel beds or extensive nerve sys-
tems, and can contribute to the development of a whole 
plethora of life threating conditions [7]. The importance of 
NCDs in low and middle income countries has recently 
been internationally recognised by the United Nations 
(UN) as a problem that perpetuates and drives poverty and 
is a “threat to human, social, and economic development” 
[9,10]. Thereby, RA not only contributes significantly to 
this burden, but also contributes by increasing the rate of 
heart disease and stroke [7], certain cancers [11], and pos-
sibly diabetes [12]. RA is also a cause of gender inequality 
as it predominantly affects woman [3]. The prevention and 
management of RA could help reduce other NCDs by re-
ducing shared risk factors and prevalence of systemic man-
ifestations [13]. A historic perspective and specific consid-
erations related to RA in the African context are provided 
in Box 1 [2,4,5,14-22].
The primary aim of this review will be to assess the preva-
lence of RA in Africa and to identify the key gaps in infor-
mation. We will also study differences in RA prevalence be-
tween rural and urban populations, between male and 
female gender, and between hospital–based and commu-
nity–based studies, aiming to identify all available, well con-
ducted studies investigating the prevalence of RA in Africa.
METHODS
Search strategy
A systematic review of the public electronic databases, Ovid 
Medline (from 1946 onwards, in–process and non–in-
dexed), Embase and Embase classic (from 1947), and 
Global Health Library (from 1910) was undertaken to find 
relevant literature. Searches using Google Scholar provided 
no additional references. Cross checking reference lists 
from review articles, editorials and study publications did 
not provide additional population based studies. The 
MeSH headings and key search terms used for Ovid Med-
line are described in Table 1. Search terms were altered 
when appropriate for other databases and the additional 
terms of prevalence, incidence and mortality were used 
alongside morbidity and burden of disease presented in the 
search strategy. All searches were completed on February 
6th, 2012.
Table 1 Search terms used in the review of the literature
1. (rheumatoid adj3 arthritis).af.
2.
exp arthritis, rheumatoid/ or exp caplan syndrome/ or exp 
felty’s syndrome/ or exp rheumatoid nodule/ or exp rheu-
matoid vasculitis/
3. (rheum* adj3 arth*).tw.
4. rheumatoid arthritis.tw.
5.
exp africa/ or exp africa, northern/ or exp algeria/ or exp 
egypt/ or exp libya/ or exp morocco/ or exp tunisia/ or exp 
“africa south of the sahara”/ or exp africa, central/ or exp 
cameroon/ or exp central african republic/ or exp chad/ or 
exp congo/ or exp “democratic republic of the congo”/ or 
exp equatorial guinea/ or exp gabon/ or exp africa, eastern/ 
or exp burundi/ or exp djibouti/ or exp eritrea/ or exp ethi-
opia/ or exp kenya/ or exp rwanda/ or exp somalia/ or exp 
sudan/ or exp tanzania/ or exp uganda/ or exp africa, south-
ern/ or exp angola/ or exp botswana/ or exp lesotho/ or exp 
malawi/ or exp mozambique/ or exp namibia/ or exp south 
africa/ or exp swaziland/ or exp zambia/ or exp zimbabwe/ 
or exp africa, western/ or exp benin/ or exp burkina faso/ or 
exp cape verde/ or exp cote d'ivoire/ or exp gambia/ or exp 
ghana/ or exp guinea/ or exp guinea-bissau/ or exp liberia/ 
or exp mali/ or exp mauritania/ or exp niger/ or exp nigeria/ 
or exp senegal/ or exp sierra leone/ or exp togo/
6. africa.tw.
7. 5 or 6
8. 1 or 2 or 3 or 4
9. (burden and disease).tw.
10. (disease adj3 burden*).tw.
11. exp morbidity/
12. morbidity.tw.
13. 9 or 10 or 11 or 12
14. 7 and 8 and 13
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Box 1 Rheumatoid arthritis in the African context
The extent of the problem caused by RA in Africa is presently uncertain, as very few epidemiological 
studies have been conducted [14]. Historically, RA in Africa has been seen as a rare disease with a mild 
onset compared to Europe and America [15], and in the face of acute life threating illness such as HIV, 
malaria, tuberculosis, and severe malnutrition, it has been largely ignored and given a low priority for 
medical research and resource allocation [16]. RA has a significant impact on the burden of disease in 
many other developing regions of Asia and South America, so it is likely the situation is similar in Africa 
[2]. Most of the data for this low prevalence and mild course has come from studies conducted between 
the 1950s and 1980s [15,16]. Since the 1980s there has been a dearth of publications concerning RA, 
which is in opposition to the trends of disease research in Africa for other fields [17], and as such the 
current burden of RA remains unknown [2]. The limited data available appears to show an increasing 
prevalence and severity of RA in Africa, particularly for urban populations [15]. The literature would 
suggest that the first reported case in Africa has only been described in 1956 [18], since when an increas-
ing number of cases have been identified across Africa. A good example is from a sequence of studies 
undertaken in a hospital in Mulago, Uganda, in which increasing number of patients with RA were iden-
tified over a period of decades. The first 6 confirmed cases were seen in 1969, but more than 400 further 
cases were seen in the same hospital by 1980 [15]. RA is believed to have first been described in the 
Americas, with evidence of its existence from records before European settlement; the first reported cas-
es in Europe only date to the 17th century [4]. This would support the hypothesis of the disease being 
triggered by an interaction with an unknown infectious agent, and it would explain rare occurrence in 
rural populations, as any spread would initially be to large settlements with international connections 
[4,19]. In addition, the estimated prevalence of 0.2–0.3% in Africa is very small compared to the 2% 
seen in Jamaica [20].
Given that any reviews of the evidence will need to rely on an almost historic set of studies in Africa, one 
of the major concerns is how did political realities of the times in which the studies were conducted re-
flect upon the demographic structure of the study sample? Many studies in this review were conducted 
in South Africa, in the period between 1975 and 1988. In those times, it is possible that the studies were 
mainly addressing the prevalence of RA in the minority of European immigrant populations, while the 
studies conducted in other African countries may have also been disproportionately capturing the rates 
within the subpopulations of European colonizers. This is particularly likely to be true for hospital–based 
studies at the time.
Despite the scarcity of information regarding the prevalence of RA in Africa, some steps have been made 
to improve the coverage and support of the rheumatic diseases. In 1989 the African League of Associa-
tions for Rheumatology (AFLAR) was created in recognition of the large burden that this group of illness 
represents [21]. In association with the Community Oriented Program for Central Control of Rheumat-
ic Diseases (COPCORD), created by WHO to record the burden caused by rheumatic disorders through 
populations surveys, AFLAR has been tasked to record and improve the care of rheumatic patients in 
Africa [22]. In diffidence to this initiative, only Egypt and Tunisia have a COPCORD centre in Africa, 
and only a single survey has been published regarding the prevalence of RA by AFLAR [22]. As it stands, 
very little significance is given to rheumatic disease in Africa, with only a single rheumatologist provid-
ing for the 16 million strong population of Kenya and thirty for the 40 million of South Africa as recent-
ly as 2003 [16].
Despite its serious health problems RA is a treatable disease if caught in the early stages [2]. A combina-
tion of disease–modifying anti–rheumatic drugs (DMARDs) and low dose steroids prescribed aggres-
sively can drastically slow down the progression of the disease and even cause remission [2]. Unfortu-
nately, the most effective biological drugs are very expensive and far beyond the means of resource–starved 
African countries [2]. An effective and cost-effective alternative to the front line drugs used in the indus-
trial nations has been developed by COPCORD and can drastically alter the prognosis of the disease [5]. 
This set of treatment guidelines uses cheap generic drugs. Initially all 5 drugs are used in combination 
until remission is achieved. Once remission is seen, the intravenous drugs are withdrawn, leaving only 
oral drugs. The aim is to maintain remission without the need for any drug therapy as a stimulus [5]. 
This is a safe, cost-effective alternative to the usual high maintenance programs and highlights the need 
for epidemiological data to map the patterns of the disease, so that implementation can be started in the 
appropriate settings to maximise the cost-effectiveness of the programme. A degree of caution is war-
ranted before certain DMARDs are prescribed in an Africa, as the immunosuppressant properties of the 
drugs can exacerbate problems associated with endemic infections such as TB, HIV, and malaria [16]. 
Some drug combinations have been shown to be safer than others but currently little research has been 
conducted and the safety parameters remain unknown [16].
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Inclusion and exclusion criteria
As few studies were expected to have been published the 
initial inclusion criteria and search strategy was broad to 
minimise overlooking any publications. The inclusion cri-
teria were: population or hospital based studies undertak-
en in Africa with a clearly expressed numerical form of dis-
ease prevalence showing a denominator population. A clear 
case definition was needed with the diagnosis of RA by a 
specified criteria of a modified or revised form of the Rome 
criteria [23], American Rheumatism Association (ARA) cri-
teria of 1959, 1961 or 1968 [24-26], or the 1987 Criteria 
by the American College of Rheumatology (ACR) [27]. No 
date limit was applied.
Any non–population based studies were excluded from the 
main analysis, but hospital based studies were retained for 
the secondary analysis and review articles for a source of 
reference. Papers with incomplete detailing on the cohort 
population, papers that excluded prevalence data, papers 
based on unsound epidemiological methods and duplicat-
ed papers were all excluded. All forms of arthritis other 
than RA where excluded, as were forms of early onset RA 
(juvenile idiopathic arthritis), which is classified as a sepa-
rate disease [28].
Systematic analysis
The initial search of Ovid Medline, Embase and Embase 
classic, and Global Health Library identified 335 papers. 
All papers deemed relevant after screening of titles were 
also screened using their abstracts; whenever abstracts were 
not available, full text sources were found and assessed. 
Any papers whose abstract or full text could not be located 
were appropriated through the InterLibrary Loan internet 
accessible database (ILLiad) and assessed once received. In 
total, 10 articles were received through ILLiad. Towards the 
end of the exclusion process, 80 articles were selected for 
abstract review, with 11 population studies and 18 hospital 
studies being identified after screening for quality and rel-
evance. Reviews of full text articles retained only 10 popu-
lation–based studies; 11 hospital studies were also kept for 
secondary aim of studying the difference in prevalence es-
timates between population and hospital–based studies. 
The literature search process is summarised in Figure 1.
Data extraction and analysis
Selected studies where extracted and analysed in an Excel 
file. Information extracted included information on the 
studies such as the title, author(s), date, journal name, pub-
lication date and quantitative data. Specific quantitative 
information was recorded for the study size and number 
of reported RA cases calculated as a proportion. Wherever 
possible, information was broken into age groups for male, 
female, and combined populations. Cases of RA were de-
fined as ‘probable’ or ‘definite’. The definition of ‘probable’ 
combined the American Rheumatism Association (ARA) 
and Rome criteria. The term ‘definite’ used the American 
College of Rheumatology (ACR) criteria. The setting of the 
paper, either rural or urban, was also recorded. This pro-
cess was repeated for hospital–based studies.
The extracts of information typically contained the average 
age of a specific age group, the size of the population with-
in this age group, and the reported prevalence. Whenever 
an open age bracket was given (ie, 75+), the average age for 
the age group was calculated using country population es-
timates from the closest year to the year of study using Unit-
ed Nations Population Division's (UNPD) data [29]. If the 
study date was between UNPD years the most recent year 
was used as the data was deemed more likely to be accurate. 
If no age break down was supplied, the data was combined 
into a single average age with prevalence and cohort size for 
the whole study. These data points were then combined into 
age subgroups of 10–year gaps, with the first interval hav-
ing a 15 year gap (0–15, 15–25, 25–35, etc.). Different sub-
groups were used for hospital studies because of different 
data distribution. Once all the data was combined into a 
single table (see Online Supplementary Document), a 
weighted prevalence was calculated using the cohort size 
for each data point. Once a prevalence and cohort size for 
each age subgroup has been found, 95% confidence inter-
Figure 1 A summary of search strategy used in this study.
Ovid Medline
n=135
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vals were calculated [30]. This process was repeated sepa-
rately in male and female groups.
To assess the number of people suffering from RA in Africa, 
the weighted prevalence was calculated for each age group 
and applied to UNPD population data for Africa in 1990 
[29]; 1990 was selected as it was the year to the period 
when most studies were conducted. The burden according 
to UNPD 2010 data was also calculated, using an estimat-
ed projection for the prevalence in 2010.
All processes specified for data analysis were repeated for 
hospital studies, population and hospital studies com-
bined, rural studies, and urban studies. Confidence inter-
vals were calculated for all of the aforementioned studies 
(see Online Supplementary Document). Hospital–based 
studies were analysed separately from population–based 
studies because they are inherently biased and unrepresen-
tative of the larger African population; only those individ-
uals living in an urban environment, with enough money 
to pay for treatment, or in the end stages of severe illnesses, 
would be expected to seek medical attention [31]. Two of 
the identified studies had more than one distinct popula-
tion group, so have been counted separately in the analysis. 
The study in the Western Cape of South Africa identified a 
rural cohort living on a reserve in Rietpoort, and an urban 
cohort living in Hout Bay [32]. Another study identified 
three cohorts, two of which were based in Nigeria and one 
in Liberia [33].
RESULTS
Study characteristics
Only a small number of studies reporting the prevalence 
of RA were identified. The majority of studies were con-
centrated in a few countries (South Africa, Nigeria and 
Uganda), while for vast areas of Africa no data was avail-
able (Figure 2). In ten population–based studies the pe-
riod of study, cohort size and setting varied widely. The date 
range was from 1968–2009, with the majority conducted 
in 1970s and 1980s. Only two papers were identified that 
were publishedafter 1990. The cohort sizes ranged from 
35 to 5120 individuals. The majority of studies were con-
ducted in rural settings. Three studies did not provide 
breakdown of their cohorts by age, and four (including 
those three) did not provide information on gender differ-
ences. Main study characteristics are provided in Table 2. 
Three different sets of criteria for defining RA were used: 
the Rome, ARA, and ACR criteria. A full list of hospital–
based study characteristics are available in Online Supple-
mentary Document. Only three hospital–based studies 
were published after 1990, and three were conducted in a 
rural setting.
Findings
We extracted all the information on sub–samples from the 
11 population–based studies which were defined by dis-
tinct age group, size of sub–sample in that age group, and 
reported prevalence for the age group. This database is vi-
Table 2 Characteristics of 10 identified population–based studies on rheumatoid arthritis
Author Country Setting Publication year RA criteria
Cohort 
size
Prevalence 
(%)
Prevalence  
(%, men only)
Prevalence  
(%, women only)
Abdel-Nasser et al [4] Egypt rural 2009 ACR 1987 [4] 5120 0.29 – –
Beighton et al [34] South Africa rural 1975 Rome 1963 [34] 801 0.87 1.60 0.40
Brighton et al [35] South Africa rural 1988 Rome 1963 [35] 543 0.00 0.00 0.00
Meyers et al [36] South Africa rural 1977 Rome 1963 w/ ARA exclusions [36] 433 2.30 – –
Meyers et al [32] South Africa rural 1982 ARA 1968 [32,36] 127 0.79 – –
Meyers et al [32] South Africa urban 1982 ARA 1968 [32,36] 35 0.57 –* –
Moolenburgh et al [37] Lesotho rural 1986 ARA 1959 [37] 1070 1.80 1.80 1.80
Muller et al [33] Uganda and Liberia rural 1972 ARA 1961 [33] 607 2.47 3.10 1.90
Silman et al [38] Nigeria rural 1993 ACR 1987 [38] 1994 0.00 0.00 0.00
Solomon et al [39] South Africa urban 1975 Rome 1963 [39,40] 551 3.27 2.60 3.70
Truswell et al [41] Botswana rural 1968 – 154 0.00 0.00 0.00
RA – rheumatoid arthritis, ARA – American Rheumatism Association
Figure 2 Geographic distribution of studies reporting prevalence 
of RA in Africa (number of studies from each country is 
indicated by different colours).
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sualized in Figure 3. There was an apparent increasing 
trend with age, which we further characterized by comput-
ing the weighted mean age for each group of sub–samples 
within the same age band, and assigning it a weighted 
mean prevalence and 95% confidence intervals (Figure 4). 
Using this information and the information on the demog-
raphy of the African population in 1990, we estimated that 
the crude prevalence of RA in Africa is 0.36%. This estimate 
is still considerably lower than the 1% for North America 
and Europe [4], but greater than the 0.2–0.3% which was 
a previous estimate for Africa [16]. If the prevalence in Fig-
ure 4 was applied to the UNPD data for African population 
size in 2010, crude prevalence would increase to 0.42%. 
These figures would translate into an overall burden of dis-
ease of over 2.5 million of people living with disease in Af-
rica according to 1990 demographic profiles, but more 
than 4 million individuals in 2010 (see Online Supplemen-
tary Document for rationales and methods behind these 
estimates).
Although the overall prevalence for Arica is 0.36%, there 
is a large variations in prevalence with age, sex, geograph-
ical region and setting. A large difference in the reported 
burden of RA was noted between population and hospital 
studies, with almost a 10-fold reduction in reporting from 
hospital reports (Online Supplementary Document).
DISCUSSION
Our literature review identified a number of population–
based studies conducted in Africa that provided informa-
tion on RA prevalence. To our knowledge, this study is the 
first systematic literature review that has combined all 
available publications on epidemiology of RA for Africa. 
Still, the scarcity of available information limits the gener-
alizability of the results presented in this manuscript. The 
consistent trend of prevalence increasing with age was seen 
in every study. The difference in reported prevalence be-
tween population and hospital studies is substantial, with 
a 6:1 ratio in favour of population studies, with a likely ex-
planation that fewer individuals with RA seek hospital care 
and most of them remain undiagnosed. Patients with acute 
illness such as infections or major trauma are more likely 
to seek medical attention, while hospitals themselves are 
unlikely to focus on identifying cases of RA given their bur-
den and lack of resources [35,42]. An unexpected finding 
of this study was the similarity between the rates reported 
for males and females [35,38]. There are many possible ex-
planations, including biases inherent to recruiting male in-
dividuals in rural population (with predominantly older 
and ill persons taking part), and cultural sensitivities sur-
rounding the positive diagnosis in females [33].
Attempts were made to reduce bias as much as possible. A 
high sensitivity search criteria with abstract screening was 
implemented to identifying as many publications as pos-
sible. By extending the search criteria to the entire Africa 
from before and after 1990 a larger number of studies were 
identified. The inclusion of North African states is often 
questioned, as their ethnic and cultural background is dis-
tinct from Sub–Saharan Africa [43]. The inclusion of pub-
lications from before 1990 was a necessity as only two stud-
ies have been conducted after 1990s. Older studies have a 
different demographic pattern, generally being smaller and 
younger than contemporary populations [29]. This is why 
we used the population of Africa in 1990 as the most ap-
propriate to estimate the overall burden.
Given that our review is based on an almost historic set of 
studies in Africa, one of the major concerns is how did po-
litical realities of the times in which the studies were con-
ducted reflect upon the demographic structure of the study 
Figure 3 Relationship between the weighted mean age (in years) 
of examinees from 10 population–based studies belonging to 
different age groups and the observed prevalence (the size of 
bubbles is proportional to sample size of each sub–sample).
Figure 4 Relationship between the weighted mean age (in years) 
of examinees from 10 population–based studies belonging to 
different age groups and the observed prevalence (with 95% 
confidence intervals).
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sample? Many studies in this review were conducted in 
South Africa, in the period between 1975 and 1988. In 
those times, it is possible that the studies were mainly ad-
dressing the prevalence of RA in the minority of European 
immigrant populations, while the studies conducted in 
other African countries may have also been disproportion-
ately capturing the rates within the subpopulations of Eu-
ropean colonizers. This is particularly likely to be true for 
hospital–based studies at the time.
One of the critical issues when estimating prevalence based 
on studies which span over such a long period of time is 
to ensure that diagnostic criteria did not change. Before 
1990 two sets of criteria were used: the Rome and ARA. 
The ARA criteria are more clinically based and not always 
applicable to studying remote communities [35]. Even the 
simplified Rome criteria would be difficult to implement, 
due to the requirement of a detailed history of polyarthri-
tis. Interpreters are often needed and detailed histories and 
can lead to ambiguous responses. Due to this difficulty, all 
papers using Rome definitions applied modified criteria 
that omitted past history, subsequently needing 2 of 3 pos-
itive findings from clinical, radiological and serological test 
being required to establish a diagnosis (rather than 3 of 4), 
which could lead to over–diagnosis. The ARA criteria ap-
pear to be more sensitive that the Rome set, but also prone 
to over–diagnosing [33]. Diagnostic tools, especially rheu-
matoid factor (RF) in serum, appear extremely unreliable 
[36,41,44]. Another problem in Africa is low participation 
rate and subsequent loss to follow up, due to simple super-
stitions and fears, cultural barriers and migration [45]. An 
incentive to motivate the population into attendance can 
greatly reduce rates of attrition, with Brighton et al 1988 
having a 97% response rate due to a free health clinic set 
up in parallel with the study to support the local popula-
tion [35].
A crude prevalence of 0.36% implied through these rare 
conducted studies, with a resulting burden of over 2 mil-
lion persona in 1990 and more than 4 million in 2010, is 
relatively small compared to that in industrialized coun-
tries. However, it is still an important cause of morbidity. 
Given the limitations of the data presented here, any re-
source allocation based on these estimates would also need 
to be provisional. The most important policy implication 
from this review is an urgent need for more studies to be 
conducted. The publications used to generate an estimate 
is based on studies more than 20 years old and concen-
trated in a few countries, with the vast majority of Africa 
having no information over the past 50 years. A distinct 
correlation between age and prevalence is evident, but the 
usual gender ratios were not observed. More studies with 
better controlling for population bias are needed to confirm 
whether this is a true finding, so that programmes can be 
tailored to target high risk groups more effectively. This pa-
per succeeded in revealing the importance of population–
based estimates over hospital–based ones, as extensive un-
der–reporting was noticed in hospital–based studies.
The basic infrastructure, with the African League of Asso-
ciations for Rheumatology (AFLAR), is already present and 
should be built on to improve the coverage and research of 
RA. Despite the creation of AFLAR, little has been done to 
further the understanding of the epidemiology of RA in Af-
rica. Cheap and effective treatments are available [5], so it 
is imperative that more studies are conducted to identify 
the true burden of RA and properly implement treatment.
Currently, this systematic review presents the only available 
systematic study of the burden of RA in Africa and it is sug-
gestive of a larger prevalence than previously thought. This 
estimate is based on limited data, and further research is 
needed to consolidate our understanding of the true prev-
alence. Suggestions for future research are to use full (or 
randomly selected) area census, with a large cohort size (of 
more than 2000–3000 participants) using the ACR criteria 
as the most reliable diagnostic criteria currently available 
[27]. Local groups should be involved, particularly AFLAR 
and local clinics, as they have an existing capacity to mon-
itor the population and their involvement may encourage 
increased interest and awareness of RA as an emerging Af-
rican health problem.
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